FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileImmuron Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
IMC.AX
Immuron Limited Stock AnalysisComprehensive stock analysis for Immuron Limited (IMC.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisIMC.AX
IMC.AX
Immuron Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
IMC.AX
  1. Home
  2. Stocks
  3. Immuron Limited

Immuron Limited

🇦🇺IMC.AX•ASX

Immuron Limited

🇦🇺IMC.AX•ASX

Your view on IMC.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Immuron Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Steven George Lydeamore
Headquarters
62 Lygon Street, Carlton, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Steven George Lydeamore
Headquarters
62 Lygon Street, Carlton, VIC, AU
Description

Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies.

Operating across two divisions—Research and Development, and Hyperimmune Products—the company serves markets in Australia, Israel, Canada, the United States, and other international regions.

Its current product portfolio includes Travelan, an over-the-counter remedy aimed at reducing the likelihood of travelers' diarrhea and minor gastrointestinal complaints, which also functions as a dietary supplement for digestive well-being and gut protection.

Another offering, Protectyn, is an immune supplement formulated to bolster healthy digestive function and liver support. Beyond its commercialized products, Immuron is actively progressing several pipeline candidates.

Travelan (IMM-124E) is currently undergoing a Phase III registration trial in the United States for the prevention of travelers' diarrhea, alongside a Phase II field trial for the same indication, and has demonstrated antiviral efficacy against SARS-CoV-2.

Concurrently, IMM-529 is in Phase I/IIa clinical trials, targeting patients with recurrent Clostridium difficile infections.

The company has also established key research alliances, including an agreement with the Naval Medical Research Center to develop and clinically evaluate a therapeutic agent against Campylobacter and enterotoxigenic Escherichia coli infections, and a collaborative effort with the Walter Reed Army Institute of Research to create an oral treatment for shigellosis.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Immuron Limited. Starting points for Immuron Limited: EPS -AUD 0.01, beta 0.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Immuron Limited. Immuron Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Immuron Limited. Trailing twelve-month EPS for Immuron Limited stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · AUD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent QtrJun 2018Next QtrDec 2024Current YearFY Jun 2017Next YearFY Jun 2018
Avg. estimate−AUD 0.13−AUD 0.00−AUD 0.16−AUD 0.04
Low estimate−AUD 0.13−AUD 0.00−AUD 0.16−AUD 0.04
High estimate−AUD 0.12−AUD 0.00−AUD 0.16−AUD 0.04
No. of analysts2111
Year-ago EPS————
Growth————

Revenue Estimate

RevenueCurrent QtrJun 2018Next QtrDec 2024Current YearFY Jun 2017Next YearFY Jun 2018
Avg. estimateAUD 2.58MAUD 4.02MAUD 1.82MAUD 2.99M
Low estimateAUD 2.46MAUD 4.02MAUD 1.82MAUD 2.99M
High estimateAUD 2.59MAUD 4.02MAUD 1.82MAUD 2.99M
No. of analysts2111
Year-ago revenue————
Growth————

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Immuron Limited. Immuron Limited has reported as a listed company since 1999. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold IMC.AX20 companies
Compare IMC.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
AT1.AXAtomo Diagnostics LimitedHealthcareMedical - Devices—
AVE.AXAvecho Biotechnology LimitedHealthcareBiotechnology—
BTC.AXBTC Health LimitedHealthcareBiotechnology—
ENL.AXEnlitic, Inc.HealthcareMedical - Healthcare Information Services—
NC6.AXNanollose LimitedHealthcareBiotechnology—
NOX.AXNoxopharm LimitedHealthcareBiotechnology—
NTI.AXNeurotech International LimitedHealthcareBiotechnology—
OSL.AXOncoSil Medical LtdHealthcareMedical - Devices—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PAR.AXParadigm Biopharmaceuticals LimitedHealthcareASX—
PARDPoniard Pharmaceuticals, Inc.HealthcareOTC$150
PASGPassage Bio, Inc.HealthcareNASDAQ$12.9M
PBIGFParadigm Biopharmaceuticals LimitedHealthcareOTC$87.9M
PBLAPanbela Therapeutics, Inc.HealthcareOTC$53,889
PBLSParabilis Medicines, Inc.HealthcareNASDAQ$3.5B
PBMPsyence Biomedical Ltd.HealthcareNASDAQ$47,738
PBMWWPsyence Biomedical Ltd. WarrantHealthcareNASDAQ$869
PBYIPuma Biotechnology, Inc.HealthcareNASDAQ$373.3M
PCSAProcessa Pharmaceuticals, Inc.HealthcareNASDAQ$4.8M
PCVXVaxcyte, Inc.HealthcareNASDAQ$9.3B
PDSBPDS Biotechnology CorporationHealthcareNASDAQ$43.8M
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Immuron Limited. Coverage tracks Immuron Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Immuron Limited.

IMC.AX AnalysisFair
Past
1
Growth
5
Health
5
Profit
1
Value
1

News

Latest Market News